In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.61 million shares changing hands with its beta currently measuring 2.23. Company’s recent per share price level of $0.28 trading at $0.0 or 1.08% at ring of the bell on the day assigns it a market valuation of $72.07M. That closing price of ADAP’s stock is at a discount of -428.57% from its 52-week high price of $1.48 and is indicating a premium of 28.57% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 931.18K if we extend that period to 3-months.
For Adaptimmune Therapeutics Plc ADR (ADAP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.50. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Adaptimmune Therapeutics Plc ADR’s shares saw a change of -77.99% in year-to-date performance and have moved 4.06% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of 9.05% in past 30-days. Number of shares sold short was 4.56 million shares which calculate 3.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 90.67% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -257.14% in reaching the projected high whereas dropping to the targeted low would mean a loss of -257.14% for stock’s current value.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
This year revenue growth is estimated to fall -71.80% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.18M for the same. And 8 analysts are in estimates of company making revenue of 14.4M in the next quarter. Company posted 128.23M and 40.9M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 26.53% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -75.44% while estimates for its earnings growth in next 5 years are of -24.90%.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Insiders are in possession of 0.63% of company’s total shares while institution are holding 44.16 percent of that, with stock having share float percentage of 44.44%. Investors also watch the number of corporate investors in a company very closely, which is 44.16% institutions for Adaptimmune Therapeutics Plc ADR that are currently holding shares of the company. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ADAP for having 38.97 million shares of worth $38.0 million. And as of 2024-06-30, it was holding 2.5415 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 27.4 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.787 of outstanding shares, having a total worth of $26.72 million.
On the other hand, SPDR INDEX SHARES FUNDS-SPDR Portfolio Developed World ex-US ETF and SEI INSTITUTIONAL INTERNATIONAL TRUST-SIT International Equity Fund are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 285.18 shares of worth $79707.0 or 0.11% of the total outstanding shares. The later fund manager was in possession of 225.79 shares on May 31, 2025 , making its stake of worth around $63109.0 in the company or a holder of 0.09% of company’s stock.
